Skip to content

Drug-eluting Balloon versus standard balloon angioplasty for the treatment of in-stent restenosis in the femoral-popliteal artery: a randomized, controlled prospective study

Drug-eluting Balloon versus standard balloon angioplasty for the treatment of in-stent restenosis in the femoral-popliteal artery: a randomized, controlled prospective study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004848
Enrollment
Unknown
Registered
2014-04-03
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In-stent restenosis of the femoral-popliteal artery

Interventions

1:Drug-eluting Balloon. Percutaneous transluminal angioplasty.
2:Percutaneous transluminal angioplasty

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years old; both male and female are adimitted; 2. Ever underwent the bare-metal stenting angioplasty in the femoral-popliteal artery for the treatment of arteriosclerosis obliterans; 3. Intermittent claudication or critical limb ischemia 7 days after stenting angioplasty, referred as Rutherford classification (category 2, 3, and 4); 4. More than 50% restenosis in the minimal luminal diameter within the stent-cover vessel, plus the 10-mm segments proximally and distally, compared to the mean diameter stent diameter measured by computed tomographic angiography (CTA); 5. Single vessel runoff or better with at least 1 of 3 vessels (the anterior tibial artery, theposterior tibial artery and the peroneal artery) patent to the lower third of the calf; 6. Treatment and follow-up should be voluntary and a informed consent form would be signed by the patient or legal guardian.

Exclusion criteria

Exclusion criteria: 1) Patients have a paclitaxel allergy or a iodine allergy; 2) Patients are younger than 18 years of age, or more than or equal to 80 years; 3) Patient with current medical condition with a life expectancy less than 3 months; 4) The patient had sympomatic myoinfarction within 3 months or uncontrollable heart failure; 5) The patient had severe respiratory failure (PO250 mmHg); 6) The patient had renal failure with creatine level more than 200 umol/L; 7) The patient had severe liver disfunction with alanine aminotransferase level over 3 times.

Design outcomes

Primary

MeasureTime frame
Luminal restenosis rate within the stent-cover vessel, plus the 10-mm segments proximally and distally by doppler ultrasound;peak systolic velocity ratio relative to the adjacent segment;

Secondary

MeasureTime frame
Ankle Brachial Index (ABI);Intimal thickness of lesion segment by doppler ultrasound;Pulse wave velocity(PWV);

Contacts

Public ContactShen Chenyang

Peking University People's Hospital

scy@pkuph.edu.cn+86 13311198368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026